pharmacy benefit managers, to integrate or avoid duplicating their educational programs or requirements? What other steps might FDA consider to make implementation less burdensome and more effective?

IV. Additional Matters for Consideration

1. What other steps should FDA take to operationalize the above described goals?
2. Are there additional policy steps FDA should consider relating to the OPSC that are not identified in this notice?

We invite interested parties to review these questions and submit comments to the docket for the OPSC to consider. In addition, we invite interested parties to submit additional policy considerations or recommendations for actions that FDA could or should undertake to help the Agency better address the opioid addiction crisis.

V. References


Dated: September 26, 2017.

Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.

[FR Doc. 2017–20905 Filed 9–28–17; 8:45 am]
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS—Continued

<table>
<thead>
<tr>
<th>Data collection task</th>
<th>Instrument/form name</th>
<th>Number of respondents</th>
<th>Number responses/respondent</th>
<th>Average burden/response (in hours)</th>
<th>Total response burden (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept interviews</td>
<td>Focus Group</td>
<td>975</td>
<td>1</td>
<td>1.50</td>
<td>1,462.5</td>
</tr>
<tr>
<td>Cognitive testing of instruments</td>
<td>Interview</td>
<td>5,250</td>
<td>1</td>
<td>5/60</td>
<td>437.50</td>
</tr>
<tr>
<td></td>
<td>Screener</td>
<td>150</td>
<td>1</td>
<td>10/60</td>
<td>25</td>
</tr>
<tr>
<td>Web-based surveys</td>
<td>Cognitive Test</td>
<td>50</td>
<td>1</td>
<td>2.00</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Screener</td>
<td>30,000</td>
<td>1</td>
<td>5/60</td>
<td>2,500</td>
</tr>
<tr>
<td></td>
<td>Survey</td>
<td>10,000</td>
<td>1</td>
<td>15/60</td>
<td>2,500</td>
</tr>
<tr>
<td>Omnibus surveys</td>
<td>Survey</td>
<td>3,100</td>
<td>1</td>
<td>10/60</td>
<td>350</td>
</tr>
<tr>
<td>Gatekeeper reviews</td>
<td>Review</td>
<td>325</td>
<td>1</td>
<td>30/60</td>
<td>162.5</td>
</tr>
<tr>
<td>Card sorting</td>
<td>Screener</td>
<td>600</td>
<td>1</td>
<td>10/60</td>
<td>300</td>
</tr>
<tr>
<td></td>
<td>Card Sort</td>
<td>200</td>
<td>1</td>
<td>1.00</td>
<td>200</td>
</tr>
<tr>
<td>Usability and prototype testing of</td>
<td>Screener</td>
<td>1,800</td>
<td>1</td>
<td>10/60</td>
<td>300</td>
</tr>
<tr>
<td>materials (print and web)</td>
<td>Usability Test</td>
<td>600</td>
<td>1</td>
<td>1.00</td>
<td>600</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9,975.00</td>
</tr>
</tbody>
</table>

Darius Taylor,

Paperwork Reduction Act Reports Clearance Officer, Department of Health and Human Services.

[FR Doc. 2017–20901 Filed 9–28–17; 8:45 am]
BILLING CODE 4150–32–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of Competitive Research (SCORE) Award Applications.

Date: October 18, 2017.
Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Natcher Building, Room 3AN 18, 45 Center Drive, Bethesda, MD 20892.

Contact Person: Rebecca H. Johnson, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18C, Bethesda, MD 20892, 301–594–2771, johnsonrh@nigms.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)


Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–20858 Filed 9–28–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; P41 BTRC Application Review (2018/01).

Date: November 15–17, 2017.
Time: 6:00 p.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Boston Hotel Buckminster, 645 Beacon Street, Boston, MA 02215.

Contact Person: John P. Holden, Ph.D., Scientific Review Officer, National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, (301) 496–8947, john.holden@nih.gov.


David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–20856 Filed 9–28–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Minority Health and Health Disparities; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Minority Health and Health Disparities Special Emphasis Panel; Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS


Rebecca H. Johnson,
Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18C, Bethesda, MD 20892, 301–594–2771, johnsonrh@nigms.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)


Contact Person: John P. Holden, Ph.D., Scientific Review Officer, National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, (301) 496–8947, john.holden@nih.gov.